News
Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world.
Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.
Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...
Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...
A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback